12,325 reports of this reaction
6.3% of all TIRZEPATIDE reports
#2 most reported adverse reaction
INJECTION SITE PAIN is the #2 most commonly reported adverse reaction for TIRZEPATIDE, manufactured by Eli Lilly and Company. There are 12,325 FDA adverse event reports linking TIRZEPATIDE to INJECTION SITE PAIN. This represents approximately 6.3% of all 196,029 adverse event reports for this drug.
TIRZEPATIDE has an overall safety score of 78 out of 100. Patients taking TIRZEPATIDE who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among TIRZEPATIDE users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for TIRZEPATIDE:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 12,325 FDA reports for TIRZEPATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 6.3% of all adverse event reports for TIRZEPATIDE, making it one of the most commonly reported side effect.
If you experience injection site pain while taking TIRZEPATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.